Azienda Sanitaria Universitaria Giuliano Isontina
- Address
- Via Costantino Costantinides 2, 34128 Trieste, Italy
Eye Diseases and Glaucoma
At Azienda Sanitaria Universitaria Giuliano Isontina in Trieste, clinical research in eye diseases is focused on glaucoma, with attention to preserving vision and slowing disease progression. The trial activity in this area is aimed at testing whether a new eye treatment can help protect visual function better than standard care.
- Improving visual field preservation in progressing open-angle glaucoma
- Evaluating a potential new therapy against placebo for better disease control
This research reflects a practical goal: finding treatments that may help people maintain sight for longer while supporting routine clinical management.
Cardiovascular Diseases and Heart Failure
Clinical trials in cardiovascular diseases at this hospital site are centered on heart failure, especially patients with mildly reduced or preserved ejection fraction and systemic inflammation. The research is designed to assess whether adding a novel therapy to standard treatment can lower the risk of serious heart-related outcomes.
- Reducing the risk of cardiovascular death and heart failure events
- Testing a new treatment approach for patients with HFmrEF and HFpEF
These studies aim to improve treatment effectiveness for a complex form of heart failure where inflammation may play an important role.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 9 therapeutic areas and 15 of 47 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 47 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Sanitaria Universitaria Giuliano Isontina
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) [frontMIND] | Incyte Corp. | Phase III | Not Recruiting | Apr 2021 | — |
IMP list
lock Showing 1 of 47 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 5 | Unknown | 2019-08-01 | 2021-06-05 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.